Wastewater-based sequencing of Respiratory Syncytial Virus enables tracking of lineages and identifying mutations at antigenic sites

Jolinda de Korne-Elenbaas, Auguste Rimaite, Ivan Topolsky, David Dreifuss, Charlyne Burki, Lara Fuhrmann, Louis du Plessis, William J. Fitzsimmons, Emily E. Bendall, Tanja Stadler, Niko Beerenwinkel, Timothy R. JulianmedRxiv 2025 · DOI

TL;DR

Researchers have developed an optimized amplicon-based sequencing method to monitor Respiratory Syncytial Virus (RSV) lineages and mutations directly from wastewater. By analyzing samples from two Swiss cities over two years, the study demonstrates that wastewater genomic data accurately mirrors clinical trends and can even identify rare mutations in vaccine-target sites that clinical surveillance might miss.

What Problem Does This Paper Address?

Respiratory Syncytial Virus (RSV) is a major cause of lower respiratory tract infections, particularly dangerous for infants and the elderly. While new vaccines and monoclonal antibody treatments (immunoprophylaxis) are finally becoming available, our ability to monitor the virus is surprisingly limited.

Current clinical surveillance is often "top-heavy"—it primarily captures severe cases in hospitals, leaving a massive blind spot regarding how the virus is circulating and evolving in the general population. Furthermore, as these new medical interventions are rolled out, they will exert selective pressure on the virus. We need a robust, cost-effective way to track "escape mutations" at antigenic sites (the parts of the virus the immune system recognizes) before they compromise the effectiveness of our new tools.

Methods

The authors developed a specialized workflow for Wastewater-Based Genomic Surveillance (WBGS):

  1. Sample Processing: They collected 24-hour composite raw influent from wastewater treatment plants in Zurich and Geneva. They used a vacuum-based direct capture method for nucleic acid extraction, followed by a critical inhibitor removal step to ensure the "dirty" wastewater didn't interfere with downstream reactions.
  2. Subtyping: Before sequencing, they used digital PCR (dPCR) to determine the dominant subtype (RSV-A or RSV-B) for the season.
  3. Optimized Amplicon Sequencing: This is the core innovation. They adapted a clinical sequencing protocol for the degraded RNA found in wastewater. They used ~50 primer sets to amplify 400 bp fragments covering the whole genome. Crucially, they balanced primer concentrations—increasing the concentration for underrepresented regions and decreasing it for overrepresented ones—to achieve more uniform coverage across the viral genome.
  4. Bioinformatics: They used the V-pipe pipeline for alignment and Lollipop for "lineage deconvolution"—a mathematical approach that estimates the relative abundance of different viral lineages within a mixed environmental sample based on signature mutations.

Datasets

The study utilized several data sources:

  • Primary Dataset: Wastewater samples from Zurich and Geneva, Switzerland, spanning the 2022-2023 and 2023-2024 RSV seasons.
  • Clinical Comparison: 51 Swiss clinical RSV-A sequences from the European Nucleotide Archive (ENA) and global consensus genomes from GenSpectrum/GISAID.
  • Reference Genomes: Standard reference strains (EPI_ISL_412866 for RSV-A and EPI_ISL_1653999 for RSV-B).

Key Insights and Ideas

  • The Mirror Effect: Wastewater data wasn't just "noise"; it closely mirrored the lineage diversity seen in clinical samples. When clinical data showed a shift from RSV-B dominance (2022-23) to RSV-A dominance (2023-24), the wastewater reflected this perfectly.
  • Catching the "Hidden" Mutations: The researchers identified low-frequency mutations in the Fusion (F) gene—the primary target for vaccines and monoclonals like Nirsevimab. Some of these mutations (like RSV-B I431L) had not been reported in clinical sequences from that season, suggesting WBGS can act as an early-warning system for emerging variants.
  • Primer Balancing is Key: Standard sequencing protocols often fail in wastewater because some parts of the genome amplify better than others. By fine-tuning primer concentrations, the team achieved "near-complete" genome coverage even in complex environmental samples.
  • Lineage Dynamics: The study showed that while one lineage (B.D.E.1) dominated the first season, the second season was a "soup" of co-circulating RSV-A lineages (A.D.1, A.D.3, A.D.5), highlighting the complexity of RSV evolution.

Key Results

  • Coverage: They achieved a median genome coverage of 88% for RSV-B and 62% for RSV-A (at a read depth of ≥30). The F gene, specifically, saw median coverage as high as 96% for RSV-B.
  • Correlation: There was a significant correlation between the viral concentration measured by dPCR and the resulting genome coverage, proving that WBGS is viable even at moderate viral loads.
  • Antigetic Site Monitoring: They successfully tracked mutations at known antigenic sites (e.g., S211N and R209Q). While these specific mutations don't currently bypass Nirsevimab, the ability to track them at a "catchment-wide" scale is a major proof-of-concept.

Limitations and Future Work

  • Privacy vs. Resolution: While WBGS protects individual privacy, it cannot link specific mutations to demographic data (like age or vaccination status).
  • Short Amplicons: Using 400 bp fragments is great for degraded samples but makes it impossible to "link" mutations across the whole genome of a single virion.
  • Reference Dependency: The deconvolution method relies on high-quality clinical databases. If clinical sequencing declines, the accuracy of wastewater deconvolution may suffer.
  • Future Work: The authors suggest that regular WBGS could provide a cost-effective baseline to monitor how RSV genetic diversity shifts as vaccines are implemented globally.

Summary updated

Abstract

Abstract Respiratory Syncytial Virus (RSV) infections pose a substantial health burden, especially for vulnerable populations such as infants and the elderly. While novel immunoprophylaxis offer promising protection, many countries lack robust surveillance systems to monitor circulating RSV lineages and detect mutations that might compromise the effectiveness of these new interventions. In this study, we applied an RSV subtype-specific amplicon-based sequencing approach to obtain RSV-A and RSV-B sequences from wastewater, providing catchment-wide insights into circulating RSV lineages. RSV was amplified and sequenced from wastewater samples collected during the 2022-2023 and 2023-2024 RSV seasons from wastewater treatment plants in Zurich and Geneva, Switzerland. During the 2022-2023 season, RSV-B was the predominant subtype, with the B.D.E.1 lineage prevailing in both cities. In the 2023-2024 season, RSV-A predominated and wastewater sequence data revealed co-circulation of multiple lineages, including A.D.1, A.D.3, A.D.5, and their sub-lineages. Wastewater-derived fusion gene sequences revealed several amino acid substitutions compared to the reference genomes. Most of these corresponded to known signatures of circulating lineages. However, low-frequency, non-synonymous mutations in antigenic sites of both RSV-A and RSV-B were also identified, of which some had not been reported in clinical sequences. These findings demonstrate the potential of wastewater-based genomic surveillance to identify and track circulating RSV lineages and clinically relevant mutations. As novel RSV immunoprophylaxis measures are introduced in upcoming RSV seasons, wastewater-derived genomic RSV data provides a valuable baseline for understanding RSV diversity and future viral evolution under immunological pressure.
BibTeX
@misc{korneelenbaas2025wastewater,
  author = {Jolinda de Korne-Elenbaas and Auguste Rimaite and Ivan Topolsky and David Dreifuss and Charlyne Burki and Lara Fuhrmann and Louis du Plessis and William J. Fitzsimmons and Emily E. Bendall and Tanja Stadler and Niko Beerenwinkel and Timothy R. Julian},
  title = {{Wastewater-based sequencing of Respiratory Syncytial Virus enables tracking of lineages and identifying mutations at antigenic sites}},
  year = {2025},
  doi = {10.1101/2025.02.28.25321637},
  howpublished = {medRxiv},
}
Figure